Stevan D. Stojanovic

Stevan D. Stojanovic

Auto-generated profile, based on publicly available information

Stevan D. Stojanovic

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in European Heart Journal
Verified
Journal Article
Open access
SSStevan D Stojanović
Stevan D Stojanović
JFJan Fiedler
Jan Fiedler
JBJohann Bauersachs
Johann Bauersachs
Thomas ThumThomas Thum
Thomas Thum
DSDaniel G Sedding
Daniel G Sedding
Inflammation is a hallmark and potent driver of pathological vascular remodelling in atherosclerosis. However, current anti-inflammatory therapeutic strategies have shown mixed results. As an alternative perspective on the conundrum of chronic inflammation emerging evidence points towards a small subset of senescent cells as a critical player and central node driving atherosclerosis. Senescent cells belonging to various cell types are a dominant and chronic source of a large array of pro-inflammatory cytokines and various additional plaque destabilizing factors, being involved with various aspects of atherosclerosis pathogenesis. Antagonizing these key agitators of local chronic inflammation and plaque instability may provide a causative and multi-purpose therapeutic strategy to treat atherosclerosis. Anti-senescence treatment options with translational potential are currently in development. However, several questions and challenges remain to be addressed before these novel treatment approaches may enter the clinical setting.

28 February 2025 in Cardiovascular Research
Verified
Journal Article
Open access
SSStevan D Stojanović
Stevan D Stojanović
Thomas ThumThomas Thum
Thomas Thum
JBJohann G. Bauersachs
Johann G. Bauersachs
Accumulation of senescent cells is an increasingly recognized factor in the development and progression of cardiovascular (CV) disease (CVD). Senescent cells of different types display a pro-inflammatory and matrix remodelling molecular programme, known as the ‘senescence-associated secretory phenotype’ (SASP), which has roots in (epi)genetic changes. Multiple therapeutic options (senolytics, anti-SASP senomorphics, and epigenetic reprogramming) that delete or ameliorate cellular senescence have recently emerged. Some drugs routinely used in the clinics also have anti-senescence effects. However, multiple challenges hinder the application of novel anti-senescence therapeutics in the clinical setting. Understanding the biology of cellular senescence, advantages and pitfalls of anti-senescence treatments, and patients who can profit from these interventions is necessary to introduce this novel therapeutic modality into the clinics. We provide a guide through the molecular machinery of senescent cells, systematize anti-senescence treatments, and propose a pathway towards senescence-adapted clinical trial design to aid future efforts.

28 February 2024 in Matrix Biology
Verified
Journal Article
Closed access
EAElisavet Angeli
Elisavet Angeli
MJMaria Jordan
Maria Jordan
MOMandy Otto
Mandy Otto
SSStevan D. Stojanović
Stevan D. Stojanović
MKMorten Asser Karsdal
Morten Asser Karsdal
FGFederica Genovese
Federica Genovese

1 January 2021 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
KSKatharina Schimmel
Katharina Schimmel
SSStevan D. Stojanović
Stevan D. Stojanović
CHCheng-Kai Huang
Cheng-Kai Huang
MJMira Jung
Mira Jung
MMMartin H. Meyer
Martin H. Meyer
Thomas ThumThomas Thum
Thomas Thum
Myocardial fibrosis is a hallmark of the failing heart, contributing to the most common causes of deaths worldwide. Several microRNAs (miRNAs, miRs) controlling cardiac fibrosis were identified in recent years; however, a more global approach to identify miRNAs involved in fibrosis is missing. Functional miRNA mimic library screens were applied in human cardiac fibroblasts (HCFs) to identify annotated miRNAs inducing proliferation. In parallel, miRNA deep sequencing was performed after subjecting HCFs to proliferating and resting stimuli, additionally enabling discovery of novel miRNAs. In-depth in vitro analysis confirmed the pro-fibrotic nature of selected, highly conserved miRNAs miR-20a-5p and miR-132-3p. To determine downstream cellular pathways and their role in the fibrotic response, targets of the annotated miRNA candidates were modulated by synthetic siRNA. We here provide evidence that repression of autophagy and detoxification of reactive oxygen species by miR-20a-5p and miR-132-3p explain some of their pro-fibrotic nature on a mechanistic level. We here identified both miR-20a-5p and miR-132-3p as crucial regulators of fibrotic pathways in an in vitro model of human cardiac fibroblast biology.

14 October 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
KBKaan Bacara
Kaan Bacara
SSStevan D. Stojanovic
Stevan D. Stojanovic
CWCamilla Wohnrade
Camilla Wohnrade
AOAlma Dr. Osmanovic
Alma Dr. Osmanovic
OSOlivia Schreiber-Katz
Olivia Schreiber-Katz
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
Background: 5q-Spinal muscular atrophy (SMA) is a lower motor neuron disease. However, peripheral organ involvement might contribute to its complex clinical picture, especially in severe forms. This study evaluated frequency and characteristics of autonomic symptoms, prevalence of electrocardiographic (ECG) abnormalities, and the impact of autonomic dysfunction on quality of life (QoL) in adults with SMA. Methods: Autonomic function was assessed using the SCales for Outcomes in PArkinson’s disease-Autonomic Dysfunction (SCOPA-AUT). 12-Lead ECG was recorded. The Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), and 36-Item Short Form Health Survey (SF-36) were collected to assess motor function, fatigue, depression, and QoL. Results: Forty-three SMA patients (23 males; mean age: 37.6 ± 14.1 years) and forty-three age- and sex-matched healthy controls were included. Compared to healthy controls, SMA patients scored worse on gastrointestinal domain (2.9 ± 2.9 vs. 1.1 ± 1.5, p < 0.001) and in total SCOPA-AUT score (9.8 ± 7.3 vs. 5.7 ± 4.4, p = 0.002). More severely affected patients reported a greater burden of autonomic symptoms compared to those with milder phenotypes. Burden of autonomic symptoms correlated with QoL ( ρ = − 0.33, p = 0.028). The presence of major ECG abnormalities showed a negative correlation with SMA type ( ρ = − 0.39, p = 0.027), age at the time of testing ( ρ = − 0.45, p = 0.009), and ambulatory status ( ρ = − 0.39, p = 0.027). Conclusion: Adults with SMA demonstrate a substantial burden of autonomic symptoms, especially those with more severe disease. This burden significantly compromises patients’ QoL. Further studies are needed to better understand autonomic dysfunction in this population.